---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011867"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:11:08.869060+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q2 revenue stable at $2.4M; H1 gross margin improves to 66.1%

## Summary
- Q2 product revenue $2.404M vs $2.423M YoY; commercial portfolio AUP up 12%.
- H1 2025 revenue $4.683M (+2.3% YoY); gross margin 66.1% (vs 57.6% in H1 2024).
- Operating expenses down 31% to $8.1M; cash burn reduced 41% to $4.8M in H1.
- Sales force cut from 19 to 7 FTEs; sales per FTE up 156% in Q2.
- CEO Mike Buhle reaffirms ENDOInform milestone completion by end of 2025.

## SEC filing metadata
- accession: 0001493152-25-011867
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000149315225011867/0001493152-25-011867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000149315225011867/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011867
- JSON: https://secwatch.observer/filing/0001493152-25-011867.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.